

Leap Therapeutics, Inc.
47 Thorndike Street
Suite B1-1
Cambridge, MA 02141
(617) 714-0360

August 6, 2019

Via EDGAR

United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Donald Field

RE: Leap Therapeutics, Inc.
Registration Statement on Form S-1
Filed on July 31, 2019
File No. 333-232927

Dear Mr. Field:

In accordance with Rule 461 promulgated under the Securities Act of 1933, as amended (the "Securities Act"), the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 p.m., Eastern time, on August 8, 2019, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Morgan, Lewis & Bockius LLP, by calling Julio E. Vega at (617) 951-8901.

Very truly yours,

LEAP THERAPEUTICS, INC.

/s/ Douglas E. Onsi

Name: Douglas E. Onsi

Title: Chief Financial Officer and General Counsel

cc: Julio E. Vega, *Morgan, Lewis & Bockius LLP*
